1 – 102 of 102
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Interplay between glypican-1, amyloid-β and tau phosphorylation in human neural stem cells
(
- Contribution to journal › Article
-
Mark
Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort
2024) In Journal of Neurology(
- Contribution to journal › Article
-
Mark
Novel avenues of tau research
(
- Contribution to journal › Scientific review
-
Mark
Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology : a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial
(
- Contribution to journal › Article
-
Mark
How Do Modifiable Risk Factors Affect Alzheimer's Disease Pathology or Mitigate Its Effect on Clinical Symptom Expression?
(
- Contribution to journal › Scientific review
-
Mark
Overlaps and divergences between tauopathies and synucleinopathies : a duet of neurodegeneration
(
- Contribution to journal › Scientific review
-
Mark
Structural white matter properties and cognitive resilience to tau pathology
2024) In Alzheimer's and Dementia(
- Contribution to journal › Article
-
Mark
Plasma glial fibrillary acidic protein and tau : predictors of neurological outcome after cardiac arrest
(
- Contribution to journal › Article
-
Mark
Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation
(
- Contribution to journal › Article
-
Mark
Tau accumulation and its spatial progression across the Alzheimer’s disease spectrum
(
- Contribution to journal › Article
-
Mark
Diffusion weighted magnetic resonance spectroscopy revealed neuronal specific microstructural alterations in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Plasma N-terminal containing tau fragments (NTA-tau) : a biomarker of tau deposition in Alzheimer’s Disease
(
- Contribution to journal › Article
-
Mark
Tau-neurodegeneration mismatch reveals vulnerability and resilience to comorbidities in Alzheimer's continuum
(
- Contribution to journal › Article
- 2023
-
Mark
Towards a better understanding of fluid biomarkers for Alzheimer’s disease
2023) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients
(
- Contribution to journal › Article
-
Mark
Genetically identical twin-pair difference models support the amyloid cascade hypothesis
(
- Contribution to journal › Article
-
Mark
Longitudinal amyloid and tau PET imaging in Alzheimer's disease : A systematic review of methodologies and factors affecting quantification
(
- Contribution to journal › Scientific review
-
Mark
[18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes
(
- Contribution to journal › Article
-
Mark
Direct Conversion of Fibroblast into Neurons for Alzheimer's Disease Research : A Systematic Review
(
- Contribution to journal › Scientific review
-
Mark
Effects of Brain Pathologies on Spatiotemporal Gait Parameters in Patients with Mild Cognitive Impairment
(
- Contribution to journal › Article
- 2022
-
Mark
The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline
(
- Contribution to journal › Article
-
Mark
The future of clinical trials for Alzheimer's disease. A blood-based biomarker perspective
2022) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Tau PET Imaging in Neurodegenerative Disorders
2022) In Journal of nuclear medicine : official publication, Society of Nuclear Medicine 63. p.20-26(
- Contribution to journal › Article
-
Mark
Subtypes of Alzheimer's disease : questions, controversy, and meaning
(
- Contribution to journal › Article
-
Mark
Neuropsychiatric symptoms in early stages of Alzheimer’s disease: associations with neuropathological changes and cognitive deficits
2022) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Tau, bridging the gap between Alzheimer's and Parkinson's diseases
2022) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Locus Coeruleus Degeneration Differs Between Frontotemporal Lobar Degeneration Subtypes
(
- Contribution to journal › Article
-
Mark
Genetically identical twins show comparable tau PET load and spatial distribution
(
- Contribution to journal › Article
-
Mark
Serum biomarkers identify critically ill traumatic brain injury patients for MRI
(
- Contribution to journal › Article
-
Mark
Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease–related blood-based biomarkers : Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group
(
- Contribution to journal › Article
- 2021
-
Mark
Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid-β–negative cognitively normal individuals
(
- Contribution to journal › Article
-
Mark
Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia
(
- Contribution to journal › Article
-
Mark
The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau
(
- Contribution to journal › Article
-
Mark
Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
(
- Contribution to journal › Article
-
Mark
Reduced repetition suppression in aging is driven by tau-related hyperactivity in medial temporal lobe
(
- Contribution to journal › Article
-
Mark
A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
(
- Contribution to journal › Article
-
Mark
In vivo tau pathology is associated with synaptic loss and altered synaptic function
(
- Contribution to journal › Article
-
Mark
Tau aggregation and increased neuroinflammation in athletes after sports-related concussions and in traumatic brain injury patients – A PET/MR study
(
- Contribution to journal › Article
-
Mark
Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers
(
- Contribution to journal › Article
-
Mark
Tau-related grey matter network breakdown across the Alzheimer’s disease continuum
(
- Contribution to journal › Article
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
(
- Contribution to journal › Article
-
Mark
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts
(
- Contribution to journal › Article
-
Mark
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau
(
- Contribution to journal › Article
-
Mark
Sex differences in off-target binding using tau positron emission tomography
(
- Contribution to journal › Article
- 2020
-
Mark
Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid tau fragment correlates with tau PET : a candidate biomarker for tangle pathology
(
- Contribution to journal › Article
-
Mark
Cerebro-spinal fluid biomarker levels : phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course - A joint PhD student course at University College London and University of Gothenburg
(
- Contribution to journal › Scientific review
-
Mark
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
(
- Contribution to journal › Article
-
Mark
Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Propagation of Tau Pathology : Integrating Insights From Postmortem and In Vivo Studies
(
- Contribution to journal › Scientific review
-
Mark
Longitudinal atrophy in early Braak regions in preclinical Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Compensating for choroid plexus based off-target signal in the hippocampus using 18F-flortaucipir PET
(
- Contribution to journal › Article
-
Mark
Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF
(
- Contribution to journal › Article
-
Mark
The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
(
- Contribution to journal › Article
-
Mark
Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Tau PET and relative cerebral blood flow in dementia with Lewy bodies : A PET study
(
- Contribution to journal › Article
-
Mark
Relevance of biomarkers across different neurodegenerative
(
- Contribution to journal › Scientific review
-
Mark
Relationship between cortical iron and tau aggregation in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease
(
- Contribution to journal › Article
- 2019
-
Mark
Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration
(
- Contribution to journal › Article
-
Mark
A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies
(
- Contribution to journal › Article
-
Mark
Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia : An elusive quest
(
- Contribution to journal › Article
-
Mark
Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort
(
- Contribution to journal › Article
-
Mark
Alzheimer's pathology targets distinct memory networks in the ageing brain
(
- Contribution to journal › Article
-
Mark
Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum
(
- Contribution to journal › Article
-
Mark
Distinct Conformations, Aggregation and Cellular Internalization of Different Tau Strains
(
- Contribution to journal › Article
- 2018
-
Mark
Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
2018) p.221-252(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease : Perspectives from the Research Roundtable
(
- Contribution to journal › Scientific review
-
Mark
Sex-specific genetic predictors of Alzheimer’s disease biomarkers
(
- Contribution to journal › Article
-
Mark
Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease : a cohort study
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid biomarker levels: Total tau and phosphorylated tau as markers for rate of progression in Alzheimer’s disease.
2018) Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting 2018(
- Contribution to conference › Abstract
-
Mark
No association of salivary total tau concentration with Alzheimer's disease
(
- Contribution to journal › Article
- 2017
-
Mark
Increased basal ganglia binding of 18F-AV-1451 in patients with progressive supranuclear palsy
(
- Contribution to journal › Article
-
Mark
18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Tau pathology distribution in Alzheimer's disease corresponds differentially to cognition-relevant functional brain networks
(
- Contribution to journal › Article
-
Mark
Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40)
(
- Contribution to journal › Article
-
Mark
Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid
(
- Contribution to journal › Article
-
Mark
Cerebrovascular and amyloid pathology in predementia stages : The relationship with neurodegeneration and cognitive decline
(
- Contribution to journal › Article
- 2016
-
Mark
18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease
(
- Contribution to journal › Article
- 2015
-
Mark
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
(
- Contribution to journal › Article
- 2013
-
Mark
Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment
(
- Contribution to journal › Article
- 2012
-
Mark
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI
(
- Contribution to journal › Article
- 2011
-
Mark
Multidimensional Treatment Foster Care (MTFC): Results from an independent replication
(
- Contribution to journal › Article
- 2010
-
Mark
No Association of VEGF Polymorphims with Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer's disease
(
- Contribution to journal › Scientific review
-
Mark
Co-occurrence of Alzheimer's disease β-amyloid and tau pathologies at synapses
(
- Contribution to journal › Article
- 2009
-
Mark
Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Alzheimer's disease: No effect of the CDK5 gene on CSF biomarkers, neuropathology or disease risk
(
- Contribution to journal › Article
-
Mark
Immunotherapy for Alzheimer disease
(
- Contribution to journal › Article
- 2006
-
Mark
CSF Biomarkers for Alzheimer's Disease: Levels of beta-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival.
(
- Contribution to journal › Article
- 2005
-
Mark
Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease
(
- Contribution to journal › Article
- 2003
-
Mark
A novel tau mutation in exon 9 (1260V) causes a four-repeat tauopathy
(
- Contribution to journal › Article